Thursday, January 26, 2023
WELCOME EDUCATIONAL DINNER BUFFET
19.00 Buffet opening
Friday, January 27, 2023
8.30-8.40 Opening
Heinz Ludwig and Jesús F. San-Miguel
MYELOMA BIOLOGY AND RISK STRATIFICATION
Moderator: Heinz Ludwig
8.40-9.00 Molecular pathogenesis of MM
Niccolò Bolli
9.00-9.20 The role of the immune environment in evolution and course of myeloma
Charlotte Pawlyn
9.20-9.40 Genetic risk classification of multiple myeloma
Jill Corre
9.40-10.10 Discussion around important questions
• Do genomic patterns predict progression of SMM
• Should MGUS/SMM be classified according genomic patterns
• What can be done to modify the immune environment
• Has the time come for revision of risk factors
• Are epigenetic compounds underused
10.10-10.30 BREAK
NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT
Moderator: Jesús San Miguel
10.30-10.50 MRD based treatment decisions - ready for clinical practice?
Bruno Paiva
10.50-11.10 Standard and novel imaging approaches in multiple myeloma
Elena Zamagni
11.10-11.30 Circulating plasma cells and mass spectrometry for diagnosis, disease evaluation, and prognostication
Noemi Puig
11.30-12.00 Discussion around important questions
• Requirements of regulatory agencies for approving MRD
• Circulating plasma cells for disease and response assessment
• Optimizing imaging technologies – MRI and PET/CT
• Impact of higher M-protein detection sensitivity (MGUS and MRD)
• MRD assessment and MGUS-like MM
WORKSHOPS
12.00-12.45 Prevention and treatment of bone disease
Evangelos Terpos
12.00-12.45 Management of patients with high-risk disease
Francesca Gay
12.00-12.45 MGRS and management of cast nephropathy induced acute renal failure
Graham Jackson
12.45- 13.45 LUNCH
MANAGEMENT OF PATIENTS WITH SMOLDERING AND TRANSPLANT ELIGIBLE DISEASE
Moderator: Heinz Ludwig
13.45-14.05 Risk classification of MGUS and SMM
Heinz Ludwig
14.05-14.25 Is autologous transplantation still the optimal approach in young patients?
Philippe Moreau
14.25-14.45 Expanding options for maintenance treatment
Michele Cavo
14.45-15.15 Discussion around important questions
• Can prediction of early progression in SMM be further improved?
• Upfront ASCT yields longer PFS but similar OS compared to delayed or no ASCT. Does this principle apply to SMM as well?
• What is the optimal number of induction and consolidation cycles?
• MRD guide therapy ready for prime time?
• Maintenance therapy tomorrow?
15.15-15.35 BREAK
MANAGEMENT OF TRANSPLANT INELIGIBLE PATIENTS
Moderator: Jesús San Miguel
15.35-15.55 Classification of fitness and comorbidities of patients not eligible for ASCT
Alessandra Larocca
15.55-16.15 How do I select treatment for TNE patients? Pros and Cons for continued treatment
Thierry Facon
16.15-16.45 Discussion of important questions
• Treatment of very elderly patients
• Myeloma related versus other comorbidities
• Initiation of therapy at biochemical progression
• Treatment duration
• Impact of individual risk on treatment selection
16.45-17.30 WORKSHOPS (repeated)
KEYNOTE LECTURE
17.30-18.00 Multiple myeloma research and treatment on the move. A look into the future
Jesús San-Miguel
Saturday, January 28, 2023
THE BEST APPROACH TO PATIENTS WITH RELAPSED/REFRACTORY DISEASE
Moderator: Heinz Ludwig
8.30-8.50 How I select therapy after relapse to one or two prior treatment lines
Maria Victoria Mateos
8.50-9.10 Treatment strategies in patients after ≥ 3 relapses
Mohamad Mohty
9.10-9.30 Recently approved drugs and new CELMoDs
Paula Rodriguez-Otero
9.30-10.00 Discussion of important questions
• Limitations of the definition of refractoriness
• Management of early relapse
• Lenalidomide refractory patients
• CD38 retreatment
• Optimizing therapy in high-risk RRMM patients
10.00-10.20 BREAK
HOT TOPICS IN MYELOMA
Moderator: Jesús San Miguel
10.20-10.40 BiTEs and monoclonal antibodies
Niels van de Donk
10.40-11.00 CAR-T cells and other cellular therapies
Hermann Einsele
11.00-11.30 Discussion of important questions
• Resistance mechanisms for CD38 antibodies
• Is there an optimal target for BiTEs and CAR-T cells?
• Pros and cons for BiTEs or CAR-T cells
• Impact of CAR-T cell persistence on outcome
• Prevention of toxicities of BiTEs and CAR-T cells
AMYLOIDOSIS AND WADENSTRÖM’S DISEASE
Moderator: Heinz Ludwig
11.30-11.50 New developments in the management of Amyloidosis
Giampaolo Merlini
11.50-12.10 New developments in the management of Waldenström’s disease
Meletios A. Dimopoulos
12.10-12.40 Discussion of important questions
• Is cure a realistic goal in amyloidosis?
• Cellular therapies in amyloidosis
• Treatment of patients failing to first-line treatment with PTK inhibitors and CD20+ base therapies
• Should anti-BCMA treatments be explored in Waldenström’s disease as 2/3 express BCMA on their tumor clones?
12.40-12.50 Closure of the meeting
Heinz Ludwig and Jesús San Miguel